chr5-1216947-T-G
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_001003841.3(SLC6A19):c.1173+2T>G variant causes a splice donor, intron change. The variant allele was found at a frequency of 0.000267 in 1,612,406 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001003841.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Publications
- Hartnup diseaseInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SLC6A19 | ENST00000304460.11 | c.1173+2T>G | splice_donor_variant, intron_variant | Intron 8 of 11 | 1 | NM_001003841.3 | ENSP00000305302.10 | |||
| SLC6A19 | ENST00000515652.5 | n.*118+2T>G | splice_donor_variant, intron_variant | Intron 7 of 10 | 2 | ENSP00000425701.1 |
Frequencies
GnomAD3 genomes AF: 0.000237 AC: 36AN: 152218Hom.: 0 Cov.: 35 show subpopulations
GnomAD2 exomes AF: 0.000296 AC: 74AN: 249668 AF XY: 0.000303 show subpopulations
GnomAD4 exome AF: 0.000271 AC: 395AN: 1460188Hom.: 0 Cov.: 36 AF XY: 0.000270 AC XY: 196AN XY: 726400 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000237 AC: 36AN: 152218Hom.: 0 Cov.: 35 AF XY: 0.000323 AC XY: 24AN XY: 74366 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Pathogenic:6
- -
This sequence change affects a donor splice site in intron 8 of the SLC6A19 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SLC6A19 are known to be pathogenic (PMID: 15286787, 15286788). This variant is present in population databases (rs142979576, gnomAD 0.07%). Disruption of this splice site has been observed in individuals with Hartnup disorder (PMID: 15286787, 15286788). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 449553). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Observed in siblings with features of Hartnup disorder who also possessed a second SLC6A19 variant (PMID: 15286788); Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Also known as IVS8+2T>G; This variant is associated with the following publications: (PMID: 25525159, 25082825, 31589614, 31908951, 15286788, 33144682, 15286787, 18484095) -
- -
- -
- -
Neutral 1 amino acid transport defect Pathogenic:4
- -
- -
- -
Variant summary: SLC6A19 c.1173+2T>G is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0003 in 249668 control chromosomes. This frequency does not allow conclusions about variant significance. c.1173+2T>G has been reported in the literature as a homozygous or compound heterozygous genotype in multiple individuals affected with Hartnup Disease (example, Kleta_2004, Azamov_2008). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
SLC6A19-related disorder Pathogenic:1
The SLC6A19 c.1173+2T>G variant is predicted to disrupt the GT donor site and interfere with normal splicing. This variant has been reported in the compound heterozygous and homozygous states in multiple individuals with Hartnup disorder (Table 1, Seow et al. 2004. PubMed ID: 15286788; Kleta et al. 2004. PubMed ID: 15286787). This variant is reported in 0.068% of alleles in individuals of European (Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/5-1217062-T-G). Variants that disrupt the consensus splice donor site in SLC6A19 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at